Bellerophon Therapeutics is a
clinical-stage biotherapeutics company.

We are focused on developing innovative therapies in the treatment of cardiopulmonary diseases. Our mission is to develop well-studied molecules deployed through innovative delivery systems to treat diseases with significant unmet clinical need.

More About Us

Our lead investigational cardiopulmonary product candidate, INOpulse is a combination drug-device therapy that we are developing for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), and pulmonary hypertension associated with sarcoidosis (PH-Sarc).

More About INOpulse

Our goal is to become a leader in developing and commercializing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases.

More About Pipeline

Bellerophon Therapeutics Inc. News Release

A Collection of Bellerophon Therapeutics Inc. News Release

Bellerophon Announces FDA Acceptance of Change to Ongoing Phase 3 REBUILD Study of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease
09/27/2022 12:30 PM

New study size of 140 patients for the REBUILD Study, without modifying trial objective or endpoints and maintaining power of >90% for the primary endpoint Independent Data Monitoring Committee agreed that the new targeted study size is appropriate Enrollment now expected to conclude in Q1 2023,

Bellerophon Provides Clinical Program Update and Reports Second Quarter 2022 Financial Results
08/15/2022 12:30 PM

WARREN, N.J. , Aug. 15, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial

Bellerophon Announces Poster Presentation at Upcoming American Thoracic Society 2022 International Conference
05/12/2022 12:30 PM

WARREN, N.J. , May 12, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced a poster presentation at the upcoming American

Bellerophon Provides Clinical Program Update and Reports First Quarter 2022 Financial Results
05/11/2022 12:30 PM

WARREN, N.J. , May 11, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial

Bellerophon Provides Clinical Program Update and Reports Full-Year 2021 Financial Results
03/31/2022 08:01 PM

WARREN, N.J. , March 31, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial


More News

 


Our lead investigational cardiopulmonary product candidate, INOpulse is a combination drug-device therapy that we are developing for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), and pulmonary hypertension associated with sarcoidosis (PH-Sarc).

More About Inopulse


Our goal is to become a leader in developing and commercializing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases.

More About Our Pipeline

Bellerophon Therapeutics Inc. News Release

A Collection of Bellerophon Therapeutics Inc. News Release

Bellerophon Announces FDA Acceptance of Change to Ongoing Phase 3 REBUILD Study of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease
09/27/2022 12:30 PM

New study size of 140 patients for the REBUILD Study, without modifying trial objective or endpoints and maintaining power of >90% for the primary endpoint Independent Data Monitoring Committee agreed that the new targeted study size is appropriate Enrollment now expected to conclude in Q1 2023,

Bellerophon Provides Clinical Program Update and Reports Second Quarter 2022 Financial Results
08/15/2022 12:30 PM

WARREN, N.J. , Aug. 15, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial

Bellerophon Announces Poster Presentation at Upcoming American Thoracic Society 2022 International Conference
05/12/2022 12:30 PM

WARREN, N.J. , May 12, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced a poster presentation at the upcoming American

Bellerophon Provides Clinical Program Update and Reports First Quarter 2022 Financial Results
05/11/2022 12:30 PM

WARREN, N.J. , May 11, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial

Bellerophon Provides Clinical Program Update and Reports Full-Year 2021 Financial Results
03/31/2022 08:01 PM

WARREN, N.J. , March 31, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial


More News